Acyclovir-Akos eye ointment 3%, 5g

The dosage regimen is the same for patients of all age groups.

A strip of ointment 10 mm long should be placed in the lower conjunctival sac 5 times a day with an interval of about 4 hours.

Treatment must be continued for at least 3 days after healing.

Composition for 1 g:

Active ingredient: acyclovir - 0.03 g.

Excipients: white soft paraffin (petroleum jelly).

Hypersensitivity to acyclovir or valacyclovir.

Pharmacodynamics

Mechanism of action

Acyclovir-AKOS is an antiviral drug that is highly effective in vitro against herpes simplex virus (HSV) types 1 and 2 and varicella-zoster virus, while being low-toxic to mammalian cells.

After entering the cells infected with HSV, acyclovir is phosphorylated to the active substance acyclovir triphosphate in the presence of viral thymidine kinase. Acyclovir triphosphate acts as a nonspecific inhibitor and substrate for viral DNA polymerase and prevents viral DNA synthesis without disrupting normal cellular processes.

Pharmokinetics

Acyclovir is rapidly absorbed by the corneal epithelium and the tissues of the outer membrane of the eye, as a result of which a concentration of the drug that is toxic to the virus is created in the intraocular fluid. Existing methods cannot detect acyclovir in the blood after external use of the drug Acyclovir-AKOS, eye ointment. Trace amounts are detected in urine, but these levels have no therapeutic value.

Overdose

In case of accidental swallowing of the full contents of the tube with the drug Acyclovir-AKOS, eye ointment, the occurrence of undesirable reactions is not expected.

Side effects

Frequency of occurrence of adverse reactions

Immune system disorders

Very rare: immediate-type hypersensitivity reactions, including angioedema.

Violations of the organ of vision

Very often: punctate superficial keratopathy, which does not require discontinuation of treatment and disappears without consequences.

Often: a transient slight burning sensation immediately after applying the ointment; conjunctivitis. Rare: blepharitis.

Use during pregnancy and breastfeeding, effects on fertility

Fertility

There is no information on the effect of the drug Acyclovir in the dosage form of tablets or lyophilisate for the preparation of a solution for infusion on female fertility. In a study of 20 male patients with normal sperm counts, it was demonstrated that oral acyclovir at doses up to 1 g per day for a period of up to 6 months does not have a clinically significant effect on sperm count, motility or morphology.

Pregnancy

The post-registration register of pregnancies treated with acyclovir contains data on pregnancy outcomes in women who took acyclovir in any dosage form. When analyzing the registry data, there was no increase in the number of birth defects in newborns whose mothers took acyclovir during pregnancy compared to the general population. At the same time, the identified congenital defects did not differ in uniformity or regularity, allowing us to assume a common cause of their occurrence.

With systemic use of acyclovir, no embryotoxic or teratogenic effects have been detected in rabbits, rats or mice in internationally recognized standard tests.

In a non-standard test on rats, fetal malformations were observed, but only with subcutaneous administration of high doses of the drug, which have a toxic effect on the maternal body. The clinical relevance of these results is unknown.

The use of the drug during pregnancy is possible only if the potential benefit to the mother outweighs the likelihood of an unknown risk to the fetus.

Breastfeeding period

Limited clinical data show that the drug is found in breast milk when used systemically, but the amount of the drug that a baby will receive when breastfeeding will be negligible.

Special conditions

Patients should be informed about the possible appearance of a slight transient burning sensation immediately after application of the drug.

Contact lenses should not be worn during drug treatment.

Influence on the ability to drive vehicles, mechanisms

There is no data.

Drug interactions

No clinically significant interactions have been identified.